Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis

被引:23
|
作者
McIntyre, William F. [1 ]
Healey, Jeff S. [1 ]
Bhatnagar, Akash K. [1 ]
Wang, Patrick [1 ]
Gordon, Jacob A. [1 ]
Baranchuk, Adrian [2 ]
Deif, Bishoy [1 ]
Whitlock, Richard P. [1 ]
Belley-Cote, Emilie P. [1 ]
机构
[1] McMaster Univ, Populat Hlth Res Inst, 237 Barton St East, Hamilton, ON L8L 2X2, Canada
[2] Queens Univ, Dept Med, 76 Stuart St, Kingston, ON K7L 2V7, Canada
来源
EUROPACE | 2019年 / 21卷 / 08期
关键词
Atrial fibrillation; Cardioversion; Vernakalant; Amiodarone; Ibutilide; Systematic review; Meta-analysis; ANTIARRHYTHMIC AGENT; RAPID CONVERSION; CONTROLLED-TRIAL; SINUS RHYTHM; EFFICACY; SAFETY; HYDROCHLORIDE; IBUTILIDE; RSD1235; PHASE-3;
D O I
10.1093/europace/euz175
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To evaluate the efficacy and safety of vernakalant for the cardioversion of atrial fibrillation (AF). Methods and results We reviewed the literature for randomized trials that compared vernakalant to another drug or placebo in patients with AF of onset <= 7 days. We used a random-effects model to combine quantitative data and rated the quality of evidence using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation). From 441 total citations in MEDLINE, EMBASE, and CENTRAL (December 2018), we identified nine trials evaluating 1358 participants. Six trials compared vernakalant to placebo, two trials compared vernakalant to ibutilide, and one trial compared vernakalant to amiodarone. We found significant methodological bias in four trials. For conversion within 90 min, vernakalant was superior to placebo [50% conversion, risk ratio (RR) 5.15; 95% confidence interval (CI); 2.24-11.84, I-2 = 91%], whereas we found no significant difference in conversion when vernakalant was compared with an active drug (56% vs. 24% conversion, RR 2.40; 95% CI 0.76-7.58, I-2 = 94). Sinus rhythm was maintained at 24 h in 85% (95% CI 80-88%) of patients who converted acutely with vernakalant. Overall, we judged the quality of evidence for efficacy to be low based on inconsistency and suspected publication bias. There was no significant difference in the risk of significant adverse events between vernakalant and comparator (RR 0.95; 95% CI 0.70-1.28, I-2 = 0, moderate quality evidence). Vernakalant is safe and effective for rapid and durable restoration of sinus rhythm in patients with recent-onset AF. Conclusion Vernakalant should be a first line option for the pharmacological cardioversion of patients with haemodynamically stable recent-onset AF without severe structural heart disease.
引用
收藏
页码:1159 / 1166
页数:8
相关论文
共 50 条
  • [41] Erratum to Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation
    S. T. Duggan
    L. J. Scott
    Drugs, 2011, 71 (3) : 381 - 381
  • [42] Rapid Cardioversion of Recent-Onset Atrial Fibrillation in the Emergency Department With Vernakalant: Insights From the Multinational Spectrum Registry
    Ritz, Beate
    Martin, Alfonso
    Merino, Jose L.
    Bager, Johan-Emil
    Domanovits, Hans
    Juhlin, Todd
    Levy, Samuel
    Weaver, W. Douglas
    Hartikainen, Juha
    Carbajosa, Jose
    CIRCULATION, 2019, 140
  • [43] Flecainide or Propafenone vs Vernakalant for Conversion of Recent-Onset Atrial Fibrillation
    Conde, Diego
    Costabel, Juan Pablo
    Aragon, Martin
    Caro, Milagros
    Ferro, Alejandra
    Klein, Andres
    Trivi, Marcelo
    Giniger, Alberto
    CANADIAN JOURNAL OF CARDIOLOGY, 2013, 29 (10)
  • [44] Vernakalant versus ibutilide for immediate conversion of recent-onset atrial fibrillation
    Vogiatzis, I
    Papavasiliou, E.
    Dapcevitch, I
    Pittas, S.
    Koulouris, E.
    HIPPOKRATIA, 2017, 21 (02) : 67 - 73
  • [45] Vernakalant: Perception of state of health in patients with a recent-onset atrial fibrillation
    Conde, Diego
    Costabel, Juan Pablo
    Aragon, Martin
    Lambardi, Florencia
    Trivi, Marcelo
    CARDIOLOGY JOURNAL, 2014, 21 (03) : 304 - 308
  • [47] A New Antiarrhythmic Drug in the Treatment of Recent-Onset Atrial Fibrillation: Vernakalant
    Vizzardi, Enrico
    Salghetti, Francesca
    Bonadei, Ivano
    Gelsomino, Sandro
    Lorusso, Roberto
    D'Aloia, Antonio
    Curnis, Antonio
    CARDIOVASCULAR THERAPEUTICS, 2013, 31 (05) : e55 - e62
  • [48] Pharmacological conversion of recent-onset atrial fibrillation: A systematic review
    Heldal, Magnus
    Atar, Dan
    SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2013, 47 (01) : 2 - 10
  • [49] Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation REPLY
    Pluymaekers, Nikki A. H. A.
    Dudink, Elton A. M. P.
    Crijns, Harry J. G. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04): : 387 - 388
  • [50] Is delayed cardioversion the better approach in recent-onset atrial fibrillation? No
    Capucci, Alessandro
    Compagnucci, Paolo
    INTERNAL AND EMERGENCY MEDICINE, 2020, 15 (01) : 5 - 7